AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2869346 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EH excretors)
Number of subjects: 34
Study 2869346 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful eradication of EH
Number of subjects: 34
Study 30296325 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bromfenac 0.09% (12 eyes)
Number of subjects: 24
Study 30296325 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical indomethacin 0.1% (12 eyes)
Number of subjects: 24
Study 26412463 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 (500 µg), Folic Acid (400 µg), and Vitamin D3 (600 IU) supplementation
Number of subjects: 2919
Study 26412463 — intervention group
Group type: COMPARATOR
Intervention: Placebo with Vitamin D3 (600 IU)
Number of subjects: 2919
Study 26412463 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 and Folic Acid supplementation
Number of subjects: 2919
Study 24922484 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-C via videoteleconferencing (VTC)
Number of subjects: 125
Study 24922484 — intervention group
Group type: COMPARATOR
Intervention: In-person treatment
Number of subjects: 125
Study 22974472 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline (2000mg/day)
Number of subjects: 60
Study 22974472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 20013068 — intervention group
Group type: EXPERIMENTAL
Intervention: Derivation cohort
Number of subjects: 10946
Study 20013068 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation cohort
Number of subjects: 10946
Study 19171089 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol controlled-infusion at 1 microg/ml
Number of subjects: 100
Study 19171089 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol controlled-infusion at 2 microg/ml
Number of subjects: 100
Study 19171089 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol controlled-infusion at 3 microg/ml
Number of subjects: 100
Study 19171089 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol controlled-infusion at 4 microg/ml
Number of subjects: 100
Study 19171089 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol controlled-infusion at 5 microg/ml
Number of subjects: 100
Study 15795184 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose atropine (LDA) 2 microg/kg
Number of subjects: 16
Study 12453930 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 1 mg kg(‐1) followed by 250 micro g kg(‐1) min(‐1)
Number of subjects: 50
Study 12453930 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 50
Study 12453930 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 50
Study 11189685 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordination and management processes of the PLCO trial
Number of subjects: 0
Study 9038691 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 22
Study 9038691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 8507448 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (50 mg orally, 6 hourly on days 5 to 10) with placebo (Study A)
Number of subjects: 6
Study 8507448 — intervention group
Group type: COMPARATOR
Intervention: Cortisol (50 mg orally, 6 hourly on days 5 to 10) with atenolol (50 mg orally, 12 hourly on days 1 to 10) (Study B)
Number of subjects: 6
Study 2886541 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial dopamine infusion after alpha-adrenoceptor blockade with phenoxybenzamine
Number of subjects: 0
Study 2886541 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial dopamine infusion
Number of subjects: 0
Study 2886541 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion after alpha-adrenoceptor blockade
Number of subjects: 0
Study 2886541 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (vascular dopamine receptor antagonist)
Number of subjects: 0
Study 31714470 — intervention group
Group type: EXPERIMENTAL
Intervention: Fracture Liaison Service (FLS) intervention with systematic longitudinal follow-up over 2 years.
Number of subjects: 532
Study 31714470 — intervention group
Group type: EXPERIMENTAL
Intervention: FLS intervention with treatment including anti-osteoporosis medication.
Number of subjects: 532
Study 31714470 — intervention group
Group type: EXPERIMENTAL
Intervention: FLS intervention with monitoring of subsequent fractures.
Number of subjects: 532
Study 31714470 — intervention group
Group type: EXPERIMENTAL
Intervention: FLS intervention with assessment of bone turnover markers.
Number of subjects: 532
Study 31714470 — intervention group
Group type: EXPERIMENTAL
Intervention: FLS intervention with evaluation of functional capacity and pain scores.
Number of subjects: 532
Study 31714470 — intervention group
Group type: EXPERIMENTAL
Intervention: FLS intervention with evaluation of quality of life scores.
Number of subjects: 532
Study 30283014 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral targeted therapies (ibrutinib, idelalisib, venetoclax)
Number of subjects: 0
Study 30283014 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation anti-CD20 monoclonal antibodies (obinutuzumab)
Number of subjects: 0
Study 30283014 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy
Number of subjects: 0
Study 30283014 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed death 1 inhibitors (pembrolizumab, nivolumab)
Number of subjects: 0
Study 30283014 — intervention group
Group type: EXPERIMENTAL
Intervention: CLL-International Prognostic Index (CLL-IPI)
Number of subjects: 0
Study 27074599 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibialis anterior (TA) vibration on
Number of subjects: 20
Study 27074599 — intervention group
Group type: COMPARATOR
Intervention: Tibialis anterior (TA) vibration off
Number of subjects: 20
Study 24879841 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight closed-loop (OCL) control
Number of subjects: 20
Study 24879841 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented therapy (control)
Number of subjects: 20
Study 22732281 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation therapy
Number of subjects: 66
Study 22732281 — intervention group
Group type: COMPARATOR
Intervention: Conventional percussive physiotherapy (control)
Number of subjects: 66
Study 20580844 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training (8-week training regimen utilizing the Method of Loci)
Number of subjects: 0
Study 20580844 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study 18928698 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin to skin care and sucrose
Number of subjects: 54
Study 18928698 — intervention group
Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 54
Study 15693728 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza virus vaccination
Number of subjects: 260
Study 15693728 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A virus vaccination
Number of subjects: 260
Study 12537200 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusive wrap dressing technique
Number of subjects: 152
Study 12537200 — intervention group
Group type: COMPARATOR
Intervention: Standard longitudinal dressings
Number of subjects: 152
Study 10380974 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambiguous, noise‐like phoneme /f/ presented among environmental sounds (non-speech context)
Number of subjects: 0
Study 10380974 — intervention group
Group type: COMPARATOR
Intervention: Ambiguous, noise‐like phoneme /f/ presented among syllables (speech context)
Number of subjects: 0
Study 8686686 — intervention group
Group type: EXPERIMENTAL
Intervention: Air abrasion (microetching) of previously failed bonded metal brackets
Number of subjects: 0
Study 8686686 — intervention group
Group type: COMPARATOR
Intervention: New untreated brackets
Number of subjects: 0
Study 1898694 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg once daily
Number of subjects: 385
Study 1898694 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil 600 mg twice daily
Number of subjects: 385
Study 31856900 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate-impregnated patch
Number of subjects: 354
Study 31856900 — intervention group
Group type: EXPERIMENTAL
Intervention: mupirocin ointment
Number of subjects: 354
Study 31856900 — intervention group
Group type: COMPARATOR
Intervention: usual exit-site care with normal saline
Number of subjects: 354
Study 29268756 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol dose escalation to achieve serum urate (SU) <6 mg/dl
Number of subjects: 183
Study 23857922 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter fluency stimuli using the letter S
Number of subjects: 211
Study 23857922 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter fluency stimuli using the letter F
Number of subjects: 211
Study 23857922 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter fluency stimuli using the letter A
Number of subjects: 211
Study 23857922 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of letter fluency performance based on university affiliation
Number of subjects: 211
Study 23857922 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of letter fluency performance based on sex
Number of subjects: 211
Study 23415976 — intervention group
Group type: COMPARATOR
Intervention: 5 a day
Number of subjects: 84
Study 23415976 — intervention group
Group type: EXPERIMENTAL
Intervention: just 1 more
Number of subjects: 84
Study 23415976 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 84
Study 21550556 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/Carboplatin (PC) - paclitaxel at a dose of 140 mg/m² and carboplatin AUC3, administered on days 1 and 15
Number of subjects: 153
Study 21550556 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine/Carboplatin (VC) - vinorelbine at a dose of 45 mg/m² orally and carboplatin AUC3, administered on days 1 and 15
Number of subjects: 153
Study 21550556 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/Carboplatin (PC)
Number of subjects: 153
Study 21550556 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine/Carboplatin (VC)
Number of subjects: 153
Study 19223527 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 40
Study 19223527 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 40
Study 19223527 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no medication)
Number of subjects: 40
Study 17931521 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracic surgery (VATS) lobectomy
Number of subjects: 25
Study 15028043 — intervention group
Group type: EXPERIMENTAL
Intervention: Mode Switching ON (MS ON)
Number of subjects: 202
Study 15028043 — intervention group
Group type: COMPARATOR
Intervention: Mode Switching OFF (MS OFF)
Number of subjects: 202
Study 11244189 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-slow hemodialysis (LD) for 6-8 hours at home
Number of subjects: 9
Study 11244189 — intervention group
Group type: COMPARATOR
Intervention: Standard hemodialysis (SD) for 3.5-4.5 hours in the dialysis center
Number of subjects: 9
Study 9693243 — intervention group
Group type: EXPERIMENTAL
Intervention: Bard BTA test
Number of subjects: 53
Study 9693243 — intervention group
Group type: COMPARATOR
Intervention: Voided Urine Cytology (VUC)
Number of subjects: 53
Study 7814344 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 64
Study 7814344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 2503114 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 691
Study 2503114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 691
Study 331402 — intervention group
Group type: EXPERIMENTAL
Intervention: Oromucosal PGE2
Number of subjects: 100
Study 331402 — intervention group
Group type: COMPARATOR
Intervention: Oral PGE2
Number of subjects: 100
Study 31918452 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib 250 mg once daily combined with EGFR-TKI
Number of subjects: 38
Study 31188514 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Radiofrequency (PRF) treatment for 6 minutes
Number of subjects: 66
Study 31188514 — intervention group
Group type: COMPARATOR
Intervention: Anterior Neurectomy
Number of subjects: 66
Study 28458049 — intervention group
Group type: EXPERIMENTAL
Intervention: TPOL-D intervention (n=51)
Number of subjects: 98
Study 28458049 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual control (n=47)
Number of subjects: 98
Study 25967124 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri-iodothyronine (T3) treatment
Number of subjects: 28
Study 25967124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 23382493 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 41
Study 23382493 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + LIRET
Number of subjects: 41
Study 23382493 — intervention group
Group type: EXPERIMENTAL
Intervention: LIRET
Number of subjects: 41
Study 21212373 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip abductor strength
Number of subjects: 31
Study 21212373 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps muscle strength
Number of subjects: 31
Study 18813917 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve growth factor (NGF) injection (5 mug) into the tibialis anterior muscle
Number of subjects: 20
Study 18813917 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline injection (0.5 ml, 5.8%) into the left and right TA
Number of subjects: 20
Study 18813917 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline injection into the contralateral TA muscle
Number of subjects: 20
Study 16307026 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) and chemotherapy
Number of subjects: 740
Study 16307026 — intervention group
Group type: EXPERIMENTAL
Intervention: High WBC counts (> or = 10,000/mm3)
Number of subjects: 740
Study 16307026 — intervention group
Group type: EXPERIMENTAL
Intervention: EM relapse
Number of subjects: 740
Study 16307026 — intervention group
Group type: COMPARATOR
Intervention: Isolated BM relapse
Number of subjects: 740
Study 15001403 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg of oral phenytoin (PO), divided in maximum doses of 400 mg every two hours
Number of subjects: 45
Study 15001403 — intervention group
Group type: COMPARATOR
Intervention: 18 mg/kg of intravenous phenytoin (IVP) at an initial infusion rate of 50 mg/min
Number of subjects: 45
Study 15001403 — intervention group
Group type: COMPARATOR
Intervention: 18 mg/kg of intravenous fosphenytoin (IVF) at an initial infusion rate of 150 mg/min
Number of subjects: 45
Study 15001403 — intervention group
Group type: COMPARATOR
Intervention: IV groups (IVP and IVF)
Number of subjects: 45
Study 10698387 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (250 microg/kg)
Number of subjects: 60
Study 10698387 — intervention group
Group type: COMPARATOR
Intervention: St Thomas cardioplegic solution (Control)
Number of subjects: 60
Study 9412257 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine at 2 micrograms/kg/min (group A, n = 10)
Number of subjects: 20
Study 9412257 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline as control (group B, n = 10)
Number of subjects: 20
Study 7505104 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMV3 (Etoposide, Cyclophosphamide, Methotrexate, Vincristine for 3 courses)
Number of subjects: 458
Study 7505104 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMV6 (Etoposide, Cyclophosphamide, Methotrexate, Vincristine for 6 courses)
Number of subjects: 458
Study 7505104 — intervention group
Group type: EXPERIMENTAL
Intervention: EI6 (Etoposide and Ifosfamide for 6 courses)
Number of subjects: 458
Study 7505104 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 458
Study 7505104 — intervention group
Group type: EXPERIMENTAL
Intervention: EI6 group
Number of subjects: 458
Study 3805750 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung radiotherapy (1,500 rad in 5 times with overlap on the mediastinum—3,000 rad) two weeks after surgery
Number of subjects: 38
Study 3805750 — intervention group
Group type: COMPARATOR
Intervention: No lung radiotherapy
Number of subjects: 38
Study 29601806 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC)
Number of subjects: 67
Study 29601806 — intervention group
Group type: COMPARATOR
Intervention: SHAM
Number of subjects: 67
Study 26541890 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Promotion Intervention
Number of subjects: 448
Study 24559953 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (RT)
Number of subjects: 119
Study 24559953 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 119
Study 24559953 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (RT) in small tumors (≤5 cm)
Number of subjects: 119
Study 24559953 — intervention group
Group type: COMPARATOR
Intervention: Control group in small tumors (≤5 cm)
Number of subjects: 119
Study 23557816 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-tasters
Number of subjects: 57
Study 23557816 — intervention group
Group type: COMPARATOR
Intervention: Non-tasters
Number of subjects: 57
Study 20660028 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU/d vitamin D supplementation
Number of subjects: 49
Study 20660028 — intervention group
Group type: COMPARATOR
Intervention: 400 IU/d (Control)
Number of subjects: 49
Study 17714967 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 6 microg/kg/d (higher dose)
Number of subjects: 16
Study 17714967 — intervention group
Group type: COMPARATOR
Intervention: GH 3 microg/kg/d (low dose)
Number of subjects: 16
Study 17225547 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine granules (1 package)
Number of subjects: 120
Study 17225547 — intervention group
Group type: COMPARATOR
Intervention: Duxil (1 tablet)
Number of subjects: 120
Study 12953047 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone at a dose of 60 mg/m2/day for 6 weeks, followed by 40 mg/m2/48 h for at least another 6 weeks
Number of subjects: 0
Study 12953047 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 0
Study 12953047 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (2 mg/kg/day for at least 8 weeks)
Number of subjects: 0
Study 12953047 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 0
Study 12953047 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 0
Study 12953047 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate day therapy of prednisone
Number of subjects: 0
Study 12953047 — intervention group
Group type: COMPARATOR
Intervention: Single and divided dosing of prednisone
Number of subjects: 0
Study 12953047 — intervention group
Group type: COMPARATOR
Intervention: Duration of relapse therapy
Number of subjects: 0
Study 10922084 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspeptic patients (n=156)
Number of subjects: 183
Study 10922084 — intervention group
Group type: COMPARATOR
Intervention: Control patients (n=27)
Number of subjects: 183
Study 10922084 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspeptic patients with suspected pancreatic disease
Number of subjects: 183
Study 10922084 — intervention group
Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 183
Study 8715742 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administration of medicines
Number of subjects: 0
Study 8715742 — intervention group
Group type: COMPARATOR
Intervention: Previous studies on self-administration
Number of subjects: 0
Study 1359317 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical chorionic villus sampling (TC CVS)
Number of subjects: 3079
Study 1359317 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal chorionic villus sampling (TA CVS)
Number of subjects: 3079
Study 1359317 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniocentesis (AC)
Number of subjects: 3079
Study 3887543 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g/day for 21 days
Number of subjects: 20
Study 3887543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31562799 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 733
Study 31562799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 733
Study 28860546 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote blood glucose telemonitoring program with feedback
Number of subjects: 85
Study 28860546 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 85
Study 26382239 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV (Lopinavir)
Number of subjects: 7
Study 26382239 — intervention group
Group type: EXPERIMENTAL
Intervention: DRV (Darunavir)
Number of subjects: 7
Study 26382239 — intervention group
Group type: EXPERIMENTAL
Intervention: Gag mutations (V7I, G49D, R69Q, A120D, Q127K, N375S, I462S)
Number of subjects: 7
Study 26382239 — intervention group
Group type: EXPERIMENTAL
Intervention: Major PI resistance mutation I84V
Number of subjects: 7
Study 23904145 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence readiness program
Number of subjects: 60
Study 21365164 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of total n-3 long chain fatty acids (Q4)
Number of subjects: 3294
Study 21365164 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of eicosapentaenoic acid (Q4)
Number of subjects: 3294
Study 21365164 — intervention group
Group type: EXPERIMENTAL
Intervention: High fish consumption (Q4)
Number of subjects: 3294
Study 19810579 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga-based Deep Relaxation Technique (DRT) for 20 minutes
Number of subjects: 86
Study 19810579 — intervention group
Group type: COMPARATOR
Intervention: Supine Rest (SR) for 20 minutes
Number of subjects: 86
Study 16919573 — intervention group
Group type: EXPERIMENTAL
Intervention: Poststress left ventricular ejection fraction (EF) lower than 51%
Number of subjects: 6713
Study 16919573 — intervention group
Group type: EXPERIMENTAL
Intervention: Poststress end-systolic volume (ESV) index greater than 27 mL/m2
Number of subjects: 6713
Study 16919573 — intervention group
Group type: EXPERIMENTAL
Intervention: Poststress EF of 51% or greater
Number of subjects: 6713